Trevena, Inc. (NASDAQ:TRVN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, October 18th. The firm currently has a $2.50 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 66.67% from the company’s current price.
According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
Several other brokerages have also recently commented on TRVN. Barclays PLC cut Trevena from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $15.00 to $2.50 in a research report on Monday, October 16th. Oppenheimer Holdings, Inc. set a $5.00 price target on Trevena and gave the stock a “buy” rating in a research report on Thursday, October 12th. HC Wainwright dropped their price target on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Finally, Cowen and Company reiterated a “buy” rating and set a $10.00 price target on shares of Trevena in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Trevena currently has an average rating of “Buy” and a consensus price target of $9.25.
Trevena (TRVN) traded up $0.02 during trading on Wednesday, hitting $1.50. The stock had a trading volume of 884,557 shares, compared to its average volume of 918,639. Trevena has a 1-year low of $1.38 and a 1-year high of $8.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.15 and a quick ratio of 7.15.
COPYRIGHT VIOLATION NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://baseballnewssource.com/markets/trevena-inc-trvn-upgraded-to-buy-at-zacks-investment-research/1722993.html.
Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its stake in shares of Trevena by 0.5% in the 2nd quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 500 shares during the last quarter. American International Group Inc. lifted its stake in shares of Trevena by 7.1% in the 1st quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,816 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Trevena by 12.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 6,402 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Trevena by 30.1% in the 2nd quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 14,880 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Trevena by 4.2% in the 1st quarter. Geode Capital Management LLC now owns 390,429 shares of the biopharmaceutical company’s stock valued at $1,432,000 after purchasing an additional 15,839 shares during the last quarter. 60.27% of the stock is currently owned by institutional investors and hedge funds.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with our FREE daily email newsletter.